On September 3, 2026, a Phase 2 clinical trial involving leuprolide was listed as recruiting. The study, registered as NCT07801664, is titled "Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer."
This trial is evaluating a short course of androgen deprivation therapy (ADT) in patients categorized as high risk within the low/intermediate risk prostate cancer group, using the ARTERA classification framework. Leuprolide is a component of the ADT regimen under investigation in this study.
The trial is currently in Phase 2 and its status is listed as recruiting, meaning it is actively enrolling participants. No outcome data, efficacy results, or safety findings have been reported at this stage of the trial.
Leuprolide is an approved compound with established regulatory status, and this trial represents ongoing clinical research into its use in a specific prostate cancer treatment context. Further updates are expected as the trial progresses through recruitment and subsequent phases.
Readers interested in additional background on leuprolide, including its approved uses and mechanism, can consult the compound overview for context.